Skip to main content
. Author manuscript; available in PMC: 2016 Apr 1.
Published in final edited form as: HIV Med. 2015 Apr;16(0 1):1–9. doi: 10.1111/hiv.12227

Figure 1. The design of the START trial.

Figure 1

Legend: ART-naïve (i.e, persons not previously using antiretroviral therapy [ART]) HIV-positive persons with normal immune function (i.e., a CD4 cell count above 500 cells/μL) are randomly allocated to start ART immediately or until the CD4 count has further decreased to levels below which the person starts to become at risk of contracting opportunistic diseases (i.e., AIDS) if left untreated; if AIDS develops when the CD4 count is still above 350 cells/μL then ART should also be initiated.